Studies have shown that SF3B1, SF3B2, and SF3B3 can regulate target gene expression by alternative splicing to promote cancer progression (Chen et al., 2017), also SF3B3 controls AS in renal cancer and SF3B4 in ovarian cancer by regulating AS of RAD52 (Diao et al., 2022). This evidence concerns the gene SF3B2 and ovarian cancer.